Gilead Sciences, Inc. stock price
Today's NASDAQ:GILD chart, history & news
Price:
61.40
USD
Change:
-1.39 (-2.21%)
Key stats
| Price open | 62.69 |
|---|---|
| Previous close | 62.79 |
| Market cap | 77.15B |
| Volume | 8.16M |
| Day high | |
| Day low | |
| Year high | 83.38 |
| Year low | 56.4 |
| Year to date change | 3.18% |
| P/E ratio | 61.40 |
Company Profile
Fundamentals
Insider Information
News
About Gilead Sciences, Inc.
Gilead Sciences Inc. casts itself as a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for addressing various unmet medical needs. The company came into being as a brainchild of Michael L Riordan in 1987.
Headquartered in Foster California, the company specializes in the development of treatments for HIV Hepatitis B Hepatitis C and Influenza. Its lead products include Descovy and Truvada for the treatment of HIV infection and Harvoni for the treatment of liver diseases.
The company has grown through mergers and acquisitions. Its biggest acquisition to date is the purchase of Pharmasset inc. in a deal that cost it $10.4 billion. Its other notable acquisition is YM Biosciences for $510 million.
Gilead Sciences Inc. went public in 1992 and got listed on the NASDAQ Stock Exchange in an Initial Public Offering that raised $86.25 million.
Company information
Company name
Gilead Sciences, Inc.
Exchange
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Daniel O'Day
Address
333 Lakeside Dr, Foster City, California, 94404-1147
Country
United States
Contact information
16505743000
Website
https://www.gilead.com/
Latest Gilead Sciences, Inc. news
14th September
Gilead Sciences to buy Immunomedics Inc for £16.32 billion
29th June
Gilead CEO talks remdesivir pricing
Gilead Sciences, Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | Q1 2020 | |
|---|---|---|---|---|
| Actual EPS | 2.11 | 1.11 | 1.68 | 1.68 |
| Consensus EPS | 1.95 | 1.44 | 1.57 | 1.57 |
| Announce Time | AMC | AMC | AMC | AMC |
| Number of Estimates | 25 | 23 | 23 | 23 |
| EPS Surprise Dollar | 0.16 | -0.33 | 0.11 | 0.11 |
| EPS Report Date | 28-10-2020 | 30-07-2020 | 29-04-2020 | 29-04-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 30-03-2020 | 30-03-2020 |
| Year Ago | 1.75 | 1.82 | 1.76 | 1.76 |
| Year Ago % Change | 20.57% | -39.01% | -4.55% | -4.55% |
Gilead Sciences, Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | 1.3 | 1.75 | 1.82 |
| Consensus EPS | 1.67 | 1.74 | 1.72 |
| Announce Time | AMC | AMC | AMC |
| Number of Estimates | 24 | 23 | 23 |
| EPS Surprise Dollar | -0.37 | 0.01 | 0.1 |
| EPS Report Date | 04-02-2020 | 23-10-2019 | 29-07-2019 |
| Fiscal End Date | 31-12-2019 | 29-09-2019 | 29-06-2019 |
| Year Ago | 1.44 | 1.84 | 1.91 |
| Year Ago % Change | -9.72% | -4.89% | -4.71% |
Gilead Sciences, Inc. income statements (2020) (USD)
| November 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Total Revenue | 6.58B | 6.58B | 5.13B | 5.52B | 5.52B |
| Cost of Revenue | 1.14B | 1.14B | 1.06B | 0.97B | 0.97B |
| Gross Profit | 5.44B | 5.44B | 4.06B | 4.55B | 4.55B |
| Research & Development | 1.16B | 1.16B | 1.30B | 1.10B | 1.10B |
| Selling General & Admin | 1.11B | 1.11B | 1.24B | 1.08B | 1.08B |
| Operating Expense | 3.41B | 3.41B | 3.60B | 3.15B | 3.15B |
| Operating Income | 3.17B | 3.17B | 1.52B | 2.38B | 2.38B |
| Other Income Expense Net | 0 | -2.35B | -4.5B | -372M | -372M |
| EBIT | 3.17B | 3.17B | 1.52B | 2.38B | 2.38B |
| Interest Income | 236M | 236M | 240M | 241M | 241M |
| Pretax Income | 825M | 825M | -2.97B | 2B | 2B |
| Income Tax | 472M | 472M | 373M | 465M | 465M |
| Minority Interest | -7M | -7M | -7M | -13M | -13M |
| Net Income | 360M | 360M | -3.34B | 1.55B | 1.55B |
| Net Income Basic | 360M | 360M | -3.34B | 1.55B | 1.55B |
Gilead Sciences, Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 5.85B | 5.57B | 5.65B | 5.25B |
| Cost of Revenue | 1.68B | 1.04B | 1B | 0.96B |
| Gross Profit | 4.17B | 4.54B | 4.65B | 4.30B |
| Research & Development | 1.90B | 4.99B | 1.16B | 1.06B |
| Selling General & Admin | 1.20B | 1.05B | 1.10B | 1.03B |
| Operating Expense | 4.79B | 7.08B | 3.26B | 3.04B |
| Operating Income | 1.06B | -1.5B | 2.39B | 2.21B |
| Other Income Expense Net | 839M | 3M | 16M | 142M |
| EBIT | 1.06B | -1.5B | 2.39B | 2.21B |
| Interest Income | 243M | 250M | 248M | 254M |
| Pretax Income | 1.90B | -1.5B | 2.41B | 2.35B |
| Income Tax | -788M | -333M | 535M | 382M |
| Minority Interest | -7M | -3M | -5M | -7M |
| Net Income | 2.70B | -1.17B | 1.88B | 1.98B |
| Net Income Basic | 2.70B | -1.17B | 1.88B | 1.98B |
Gilead Sciences, Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 5.78B | 5.60B | 5.69B | 5.14B |
| Cost of Revenue | 1.57B | 1.09B | 1.20B | 1B |
| Gross Profit | 4.21B | 4.52B | 4.50B | 4.14B |
| Research & Development | 1.13B | 0.94B | 1.19B | 0.94B |
| Selling General & Admin | 1.13B | 0.95B | 0.98B | 1B |
| Operating Expense | 3.83B | 2.97B | 3.37B | 2.94B |
| Operating Income | 1.95B | 2.63B | 2.33B | 2.20B |
| Other Income Expense Net | -0.93B | 33M | -239M | -168M |
| EBIT | 1.95B | 2.63B | 2.33B | 2.20B |
| Interest Income | 257M | 264M | 266M | 290M |
| Pretax Income | 1.02B | 2.66B | 2.09B | 2.03B |
| Income Tax | 1.01B | 565M | 267M | 494M |
| Minority Interest | 0 | 2M | 2M | 1M |
| Net Income | 3M | 2.10B | 1.82B | 1.54B |
| Net Income Basic | 3M | 2.10B | 1.82B | 1.54B |
Gilead Sciences, Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 5.98B | 6.54B | 7.13B |
| Cost of Revenue | 1.29B | 1.07B | 1.16B |
| Gross Profit | 4.69B | 5.47B | 5.97B |
| Research & Development | 0.98B | 789M | 864M |
| Selling General & Admin | 1.22B | 843M | 863M |
| Operating Expense | 3.49B | 2.70B | 2.89B |
| Operating Income | 2.50B | 3.84B | 4.24B |
| Other Income Expense Net | -369M | -167M | -126M |
| EBIT | 2.50B | 3.84B | 4.24B |
| Interest Income | 297M | 291M | 269M |
| Pretax Income | 2.13B | 3.67B | 4.12B |
| Income Tax | 5.96B | 0.96B | 1.05B |
| Minority Interest | 29M | -6M | -4M |
| Net Income | -3.87B | 2.72B | 3.07B |
| Net Income Basic | -3.87B | 2.72B | 3.07B |
Gilead Sciences, Inc. balance sheet (2020) (USD)
| November 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Current Cash | 23.98B | N.A | 6.75B | 10.05B | 10.05B |
| Receivables | 3.91B | 3.91B | 3.19B | 3.91B | 3.91B |
| Inventory | 1.01B | 1.95B | 1.05B | 0.99B | 0.99B |
| Current Assets | 30.93B | 31.92B | 24.64B | 26.95B | 26.95B |
| Other Current Assets | 2.03B | N.A | 0.98B | 0.97B | 0.97B |
| Short Term Investments | 2.03B | N.A | 12.62B | 10.97B | 10.97B |
| Long Term Investments | 29.95B | N.A | 5.80B | 7.01B | 7.01B |
| Property/Plant Equipment | 4.81B | 4.81B | 4.65B | 4.56B | 4.56B |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 12.94B | 12.94B | 13.23B | 13.50B | 13.50B |
| Tangible Assets (Net) | 389M | 13.35B | -9.47B | -6.12B | -6.12B |
| Other Assets | 6.01B | 7.10B | 3.50B | 3.60B | 3.60B |
| Total Assets | 60.88B | 60.88B | 55.93B | 59.74B | 59.74B |
| Accounts Payable | 527M | N.A | 532M | 590M | 590M |
| Other Current Liabilities | 7.48B | 9.51B | 6.12B | 5.65B | 5.65B |
| Total Current Liabilities | 9.51B | 9.51B | 10.56B | 8.88B | 8.88B |
| Total Liabilities | 43.43B | 43.41B | 37.79B | 37.56B | 37.56B |
| Long Term Debt | 27.79B | N.A | 21.10B | 22.10B | 22.10B |
| Current Long Term Debt | 1.50B | N.A | 3B | 2B | 2B |
| Minority Interest | 26M | -7M | -7M | -13M | -13M |
| Common Stock | 3.71B | 1.25B | 1.25B | 1.25B | 1.25B |
| Treasury Stock | 0 | N.A | N.A | N.A | N.A |
| Retained Earnings | 13.71B | N.A | 14.45B | 18.71B | 18.71B |
| Capital Surplus | N.A | N.A | 3.51B | 3.31B | 3.31B |
| Shareholder Equity | 17.45B | 17.47B | 18.03B | 22.07B | 22.07B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
Gilead Sciences, Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 11.63B | 9.47B | 11.24B | 16.93B |
| Receivables | 3.58B | 3.32B | 3.40B | 3.28B |
| Inventory | 0.92B | 882M | 884M | 898M |
| Current Assets | 30.30B | 28.36B | 33.73B | 34.02B |
| Other Current Assets | 1.12B | 1.02B | 1.08B | 834M |
| Short Term Investments | 13.04B | 13.67B | 17.13B | 12.08B |
| Long Term Investments | 1.66B | 4.45B | 3.22B | 2.39B |
| Property/Plant Equipment | 5.17B | 5.04B | 4.69B | 4.57B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 13.79B | 14.86B | 15.15B | 15.44B |
| Tangible Assets (Net) | -5.66B | -8.38B | -6.37B | -7.04B |
| Other Assets | 6.60B | 2.32B | 2.31B | 2.30B |
| Total Assets | 61.63B | 59.15B | 63.21B | 62.84B |
| Accounts Payable | 713M | 632M | 617M | 577M |
| Other Current Liabilities | 6.16B | 6.34B | 6.27B | 6.25B |
| Total Current Liabilities | 9.76B | 9.57B | 8.96B | 9.40B |
| Total Liabilities | 38.98B | 38.41B | 40.46B | 40.75B |
| Long Term Debt | 22.72B | 22.71B | 24.57B | 24.51B |
| Current Long Term Debt | 2.50B | 2.50B | 2B | 2.50B |
| Minority Interest | -7M | -3M | -5M | -7M |
| Common Stock | 1.27B | 1.27B | 1.27B | 1.27B |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | 19.39B | 17.62B | 19.83B | 19.33B |
| Capital Surplus | 3.05B | 2.87B | 2.68B | 2.49B |
| Shareholder Equity | 22.53B | 20.60B | 22.62B | 21.95B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Gilead Sciences, Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 17.94B | 14.57B | 13.23B | 7.64B |
| Receivables | 3.33B | 3.47B | 3.54B | 3.78B |
| Inventory | 814M | 816M | 859M | 885M |
| Current Assets | 35.84B | 34.92B | 32.73B | 30.26B |
| Other Current Assets | 743M | 1.34B | 1.75B | 0.92B |
| Short Term Investments | 13.01B | 14.73B | 13.35B | 17.04B |
| Long Term Investments | 1.57B | 2.52B | 5.87B | 8.23B |
| Property/Plant Equipment | 4.01B | 3.79B | 3.66B | 3.42B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 15.74B | 16.31B | 16.50B | 16.80B |
| Tangible Assets (Net) | -7.6B | -6.39B | -7.48B | -8.64B |
| Other Assets | 2.41B | 2.65B | 2.48B | 2.52B |
| Total Assets | 63.68B | 64.31B | 65.36B | 65.38B |
| Accounts Payable | 790M | 580M | 623M | 711M |
| Other Current Liabilities | 6.88B | 6.77B | 7.27B | 7.40B |
| Total Current Liabilities | 10.61B | 10.12B | 10.91B | 10.67B |
| Total Liabilities | 42.14B | 41.30B | 43.62B | 44.73B |
| Long Term Debt | 24.57B | 24.57B | 26.06B | 26.56B |
| Current Long Term Debt | 2.75B | 2.75B | 3B | 2.50B |
| Minority Interest | 0 | 2M | 2M | 1M |
| Common Stock | 1.28B | 1.29B | 1.30B | 1.30B |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | 19.02B | 20.71B | 19.83B | 19.20B |
| Capital Surplus | 2.28B | 2.12B | 1.84B | 1.56B |
| Shareholder Equity | 21.39B | 22.86B | 21.67B | 20.59B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Gilead Sciences, Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 7.59B | 11.51B | 8.71B |
| Receivables | 3.85B | 4.12B | 4.48B |
| Inventory | 801M | 1.14B | 1.41B |
| Current Assets | 31.82B | 35.32B | 28.59B |
| Other Current Assets | 1.03B | 0.98B | 1.10B |
| Short Term Investments | 18.56B | 17.56B | 12.90B |
| Long Term Investments | 11.18B | 12.97B | 15.48B |
| Property/Plant Equipment | 3.30B | 3.10B | 3.01B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 17.10B | 8.34B | 8.55B |
| Tangible Assets (Net) | -8.78B | 10.64B | 8.47B |
| Other Assets | 2.70B | 2.61B | 2.32B |
| Total Assets | 70.28B | 64.66B | 60.26B |
| Accounts Payable | 814M | 696M | 819M |
| Other Current Liabilities | 7.36B | 7.15B | 7.67B |
| Total Current Liabilities | 11.64B | 9.60B | 8.49B |
| Total Liabilities | 49.78B | 39.41B | 37.17B |
| Long Term Debt | 30.80B | 27.52B | 26.30B |
| Current Long Term Debt | 2.75B | 1.75B | N.A |
| Minority Interest | 29M | -6M | -4M |
| Common Stock | 1.31B | 1.31B | 1.31B |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | 19.01B | 23.69B | 21.82B |
| Capital Surplus | 1.26B | 0.91B | 733M |
| Shareholder Equity | 20.44B | 24.85B | 22.68B |
| Other Liabilities | N.A | N.A | N.A |
Gilead Sciences, Inc. cash flow (2020) (USD)
| November 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Net Income | 360M | 360M | -3.34B | 1.55B |
| Depreciation | 1.05B | N.A | 349M | 349M |
| Changes in Receivables | 719M | -719M | 713M | -325M |
| Changes in Inventories | -44M | N.A | -37M | 15M |
| Cash Change | 5.06B | N.A | -3.31B | -1.58B |
| Cash Flow | 6.25B | N.A | 2.57B | 1.44B |
| Capital Expenditures | -469M | N.A | -143M | -171M |
| Investments | N.A | N.A | -125M | -61M |
| Investing Activity (other) | N.A | N.A | 49M | -112M |
| Total Investing Cash Flows | -5.64B | N.A | -5.02B | -344M |
| Dividends Paid | N.A | N.A | -856M | -874M |
| Net Borrowings | 3.29B | N.A | N.A | -500M |
| Other Financing Cash Flows | N.A | N.A | 1M | -86M |
| Cash Flow Financing | -5.73B | N.A | -874M | -2.61B |
| Exchange Rate Effect | N.A | N.A | 26M | -61M |
Gilead Sciences, Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 2.70B | -1.17B | 1.88B | 1.98B |
| Depreciation | 350M | 347M | 348M | 359M |
| Changes in Receivables | -267M | 81M | -113M | 44M |
| Changes in Inventories | -60M | -23M | 3M | -15M |
| Cash Change | 2.16B | -1.77B | -5.69B | -1.01B |
| Cash Flow | 2.58B | 2.90B | 2.22B | 1.44B |
| Capital Expenditures | -203M | -200M | -185M | -237M |
| Investments | 840M | 2.28B | -5.79B | 364M |
| Investing Activity (other) | -206M | -4.18B | -64M | -238M |
| Total Investing Cash Flows | 431M | -2.1B | -6.04B | -111M |
| Dividends Paid | -801M | -804M | -800M | -817M |
| Net Borrowings | N.A | -1.5B | -500M | -750M |
| Other Financing Cash Flows | -17M | -30M | -7M | -68M |
| Cash Flow Financing | -896M | -2.52B | -1.86B | -2.37B |
| Exchange Rate Effect | 42M | -55M | -9M | 20M |
Gilead Sciences, Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | 3M | 2.10B | 1.82B | 1.54B |
| Depreciation | 358M | 358M | 356M | 357M |
| Changes in Receivables | 138M | 76M | 234M | 76M |
| Changes in Inventories | -119M | -157M | -20M | -14M |
| Cash Change | 3.37B | 1.34B | 5.59B | 55M |
| Cash Flow | 2.35B | 2.21B | 1.57B | 2.27B |
| Capital Expenditures | -248M | -167M | -297M | -212M |
| Investments | 2.84B | 2.23B | 5.62B | 4.59B |
| Investing Activity (other) | 140M | -38M | -82M | -20M |
| Total Investing Cash Flows | 2.74B | 2.03B | 5.24B | 4.35B |
| Dividends Paid | -736M | -742M | -740M | -753M |
| Net Borrowings | N.A | -1.75B | N.A | -4.5B |
| Other Financing Cash Flows | -22M | -40M | -10M | -414M |
| Cash Flow Financing | -1.67B | -2.9B | -1.15B | -6.6B |
| Exchange Rate Effect | -39M | -1M | -71M | 26M |
Gilead Sciences, Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -3.87B | 2.72B | 3.07B |
| Depreciation | 397M | 297M | 298M |
| Changes in Receivables | 271M | 356M | -444M |
| Changes in Inventories | -174M | -65M | -9M |
| Cash Change | -3.92B | 2.80B | -1.57B |
| Cash Flow | 2.75B | 2.69B | 3.53B |
| Capital Expenditures | -220M | -129M | -123M |
| Investments | 630M | -1.99B | -4.12B |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -10.02B | -2.11B | -4.25B |
| Dividends Paid | -682M | -682M | -680M |
| Net Borrowings | 4.27B | 2.96B | -30M |
| Other Financing Cash Flows | -189M | -20M | -63M |
| Cash Flow Financing | 3.35B | 2.17B | -880M |
| Exchange Rate Effect | -4M | 46M | 27M |
Gilead Sciences, Inc. dividends (USD)
| Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
|---|---|---|---|---|---|---|
| 14-12-2020 | 30-12-2020 | 15-12-2020 | N.A | 0.68 | Ordinary Shares | Quarterly |
| 14-09-2020 | 29-09-2020 | 15-09-2020 | N.A | 0.68 | Ordinary Shares | Quarterly |
| 11-06-2020 | 29-06-2020 | 12-06-2020 | N.A | 0.68 | Ordinary Shares | Quarterly |
| 12-03-2020 | 29-03-2020 | 13-03-2020 | N.A | 0.68 | Ordinary Shares | Quarterly |
| 12-12-2019 | 30-12-2019 | 13-12-2019 | N.A | 0.63 | Ordinary Shares | Quarterly |
| 11-09-2019 | 26-09-2019 | 12-09-2019 | N.A | 0.63 | Ordinary Shares | Quarterly |
| 12-06-2019 | 26-06-2019 | 13-06-2019 | N.A | 0.63 | Ordinary Shares | Quarterly |
| 14-03-2019 | 28-03-2019 | 15-03-2019 | N.A | 0.63 | Ordinary Shares | Quarterly |
| 13-12-2018 | 28-12-2018 | 14-12-2018 | N.A | 0.57 | Ordinary Shares | Quarterly |
| 12-09-2018 | 26-09-2018 | 13-09-2018 | N.A | 0.57 | Ordinary Shares | Quarterly |
| 13-06-2018 | 27-06-2018 | 14-06-2018 | N.A | 0.57 | Ordinary Shares | Quarterly |
| 15-03-2018 | 28-03-2018 | 16-03-2018 | N.A | 0.57 | Ordinary Shares | Quarterly |
| 14-12-2017 | 28-12-2017 | 15-12-2017 | N.A | 0.52 | Ordinary Shares | Quarterly |
| 13-09-2017 | 27-09-2017 | 14-09-2017 | N.A | 0.52 | Ordinary Shares | Quarterly |
| 13-06-2017 | 28-06-2017 | 15-06-2017 | N.A | 0.52 | Ordinary Shares | Quarterly |
| 14-03-2017 | 29-03-2017 | 16-03-2017 | N.A | 0.52 | Ordinary Shares | Quarterly |
| 13-12-2016 | 29-12-2016 | 15-12-2016 | N.A | 0.47 | Ordinary Shares | Quarterly |
| 13-09-2016 | 28-09-2016 | 15-09-2016 | N.A | 0.47 | Ordinary Shares | Quarterly |
| 13-06-2016 | 28-06-2016 | 15-06-2016 | N.A | 0.47 | Ordinary Shares | Quarterly |
| 14-03-2016 | 29-03-2016 | 16-03-2016 | N.A | 0.43 | Ordinary Shares | Quarterly |
| 14-12-2015 | 30-12-2015 | 16-12-2015 | N.A | 0.43 | Ordinary Shares | Quarterly |
| 13-09-2015 | 28-09-2015 | 15-09-2015 | N.A | 0.43 | Ordinary Shares | Quarterly |
| 11-06-2015 | 28-06-2015 | 15-06-2015 | N.A | 0.43 | Ordinary Shares | Quarterly |
Insider Roster
| Entity name | Report date | Shares held |
|---|---|---|
| Lofton Kevin E | 29-12-2020 | 53,921 |
| Dickinson Andrew D | 12-11-2020 | 32,118 |
| Parsey Merdad | 12-11-2020 | 24,019 |
| Wilfong Diane E. | 12-11-2020 | 17,971 |
| Mercier Johanna | 05-11-2020 | 17,906 |
| Horning Sandra | 07-05-2020 | 7,886 |
| BARTON JACQUELINE K | 07-05-2020 | 7,886 |
| MANWANI HARISH | 07-05-2020 | 7,886 |
| Kramer Kelly A. | 07-05-2020 | 7,886 |
| O'Day Daniel Patrick | 12-03-2020 | 163,132 |
Insider Summary
| Full name | Reported title | Total bought | Total sold | Net transacted |
|---|---|---|---|---|
| Parsey Merdad | Chief Medical Officer | 316,263 | 5,196 | 311,067 |
Insider Transactions
| Full name | Reported title | Effective date | Amount of shares | Price per share | Total cost |
|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer | 03-11-2020 | +26,270 | N.A | N.A |
| WELTERS ANTHONY | 22-10-2020 | +7,718 | N.A | N.A | |
| Whitley Richard James | 01-10-2020 | +1,434 | N.A | N.A | |
| Parsey Merdad | Chief Medical Officer | 17-08-2020 | -182 | 68.32 | 12,434.20 |
| Parsey Merdad | Chief Medical Officer | 15-08-2020 | +182 | 57.43 | +10,451.50 |
| Dickinson Andrew D | EVP, Chief Financial Officer | 10-08-2020 | +2,306 | N.A | N.A |
| Wilfong Diane E. | SVP, Controller & CAO | 10-08-2020 | +3,345 | N.A | N.A |
| Mercier Johanna | Chief Commercial Officer | 24-07-2020 | -3,587 | 73.64 | 264,147.00 |
| Rodriguez Javier | 23-06-2020 | -189 | 75.50 | 14,269.50 | |
| Rodriguez Javier | 15-06-2020 | +1,838 | N.A | N.A | |
| Dickinson Andrew D | EVP, Chief Financial Officer | 10-06-2020 | -1,691 | 77.07 | 130,325.00 |
| MANWANI HARISH | 06-05-2020 | +1,936 | N.A | N.A | |
| Lofton Kevin E | 06-05-2020 | +7,886 | N.A | N.A | |
| Whitley Richard James | 06-05-2020 | +1,936 | N.A | N.A | |
| WOLD OLSEN PER | 06-05-2020 | +1,936 | N.A | N.A | |
| BARTON JACQUELINE K | 06-05-2020 | +7,886 | N.A | N.A | |
| MANWANI HARISH | 05-05-2020 | +2,270 | N.A | N.A | |
| Pletcher Brett A | EVP,Corp Affairs & Gen Counsel | 05-05-2020 | +650 | 24.30 | +15,791.80 |
| Lofton Kevin E | 05-05-2020 | +2,270 | N.A | N.A | |
| Whitley Richard James | 05-05-2020 | +2,270 | N.A | N.A | |
| WOLD OLSEN PER | 05-05-2020 | +2,270 | N.A | N.A | |
| WILSON GAYLE E | 05-05-2020 | +2,270 | N.A | N.A | |
| Wilfong Diane E. | SVP, Controller & CAO | 04-05-2020 | +11,486 | N.A | N.A |
| Cogan John Francis | 04-05-2020 | +2,416 | N.A | N.A | |
| Cogan John Francis | 27-04-2020 | +2,413 | N.A | N.A | |
| Cogan John Francis | 20-04-2020 | -2,413 | 83.00 | 200,279.00 | |
| Cogan John Francis | 13-04-2020 | -2,413 | 75.90 | 183,147.00 | |
| Cogan John Francis | 06-04-2020 | +2,413 | N.A | N.A | |
| Richard J. Whitley | Director | 30-12-2019 | +67 | N.A | N.A |
| Kevin E. Lofton | Director | 30-12-2019 | +26 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 03-12-2019 | +5,900 | 24.30 | +143,370.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 03-12-2019 | -5,900 | 65.77 | 388,043.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 03-12-2019 | -5,900 | N.A | N.A |
| Kevin E. Lofton | Director | 27-11-2019 | -13,208 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 25-11-2019 | +15,000 | 40.56 | +608,400.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 25-11-2019 | -15,000 | 66.85 | 1,002,750.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 25-11-2019 | -15,000 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 19-11-2019 | -10,000 | 64.91 | 649,100.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 19-11-2019 | -10,000 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 19-11-2019 | +10,000 | 24.30 | +243,000.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 18-11-2019 | -10,000 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 18-11-2019 | +10,000 | 24.30 | +243,000.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 18-11-2019 | -10,000 | 63.85 | 638,500.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 14-11-2019 | -762 | N.A | N.A |
| Merdad V. Parsey | Chief Medical Officer | 10-11-2019 | +88,315 | N.A | N.A |
| Merdad V. Parsey | Chief Medical Officer | 10-11-2019 | +15,300 | N.A | N.A |
| Andrew D. Dickinson | EVP, Chief Financial Officer | 10-11-2019 | -1,133 | N.A | N.A |
| Andrew D. Dickinson | EVP, Chief Financial Officer | 10-11-2019 | +7,650 | N.A | N.A |
| Andrew D. Dickinson | EVP, Chief Financial Officer | 10-11-2019 | +44,160 | N.A | N.A |
| Andrew D. Dickinson | EVP, Chief Financial Officer | 10-11-2019 | -521 | 65.38 | 34,062.98 |
| Andrew D. Dickinson | EVP, Chief Financial Officer | 10-11-2019 | +1,133 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 05-11-2019 | -2,095 | 66.06 | 138,395.70 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 01-11-2019 | -2,400 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 01-11-2019 | +2,400 | 16.89 | +40,536.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 01-11-2019 | -4,000 | 64.52 | 258,080.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 01-11-2019 | -2,400 | N.A | N.A |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 01-11-2019 | -4,000 | 64.52 | 258,080.00 |
| Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | 01-11-2019 | +2,400 | 16.89 | +40,536.00 |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 28-10-2019 | -5,677 | 63.31 | 359,410.87 |
| Kevin E. Lofton | Director | 01-10-2019 | +21,527 | N.A | N.A |
| Kevin E. Lofton | Director | 01-10-2019 | -21,527 | N.A | N.A |
| Richard J. Whitley | Director | 27-09-2019 | +68 | N.A | N.A |
| Kevin E. Lofton | Director | 27-09-2019 | +240 | N.A | N.A |
| Per Wold-Olsen | Director | 28-08-2019 | +4,908 | 23.76 | +116,614.08 |
| Per Wold-Olsen | Director | 28-08-2019 | -4,908 | 63.91 | 313,670.28 |
| Per Wold-Olsen | Director | 28-08-2019 | -4,908 | N.A | N.A |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 19-08-2019 | -608 | 64.35 | 39,124.80 |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 10-08-2019 | +1,070 | N.A | N.A |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 10-08-2019 | -462 | 65.24 | 30,140.88 |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 10-08-2019 | -1,070 | N.A | N.A |
| Johanna Mercier | Chief Commercial Officer | 24-07-2019 | +148,110 | N.A | N.A |
| Johanna Mercier | Chief Commercial Officer | 24-07-2019 | +30,020 | N.A | N.A |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 23-07-2019 | -7,200 | 65.07 | 468,504.00 |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 23-07-2019 | +7,200 | 24.90 | +179,280.00 |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 23-07-2019 | -7,200 | N.A | N.A |
| Kevin E. Lofton | Director | 27-06-2019 | +223 | N.A | N.A |
| Kevin E. Lofton | Director | 27-06-2019 | +223 | N.A | N.A |
| Richard J. Whitley | Director | 27-06-2019 | +64 | N.A | N.A |
| Brett A. Pletcher | EVP, Gen Counsel & Corp Sec | 18-06-2019 | -5,816 | 68.75 | 399,850.00 |